SPPAM
UTHR icon

Summit Partners Public Asset Management’s United Therapeutics UTHR Stock Holding History

Summit Partners Public Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-36,878
Closed -$10.3M – 134
2022
Q4 		$10.3M Buy
+36,878
New +$9.31M 0.65% 50
2022
Q1 		– Sell
-133,592
Closed -$28.9M – 167
2021
Q4 		$28.9M Buy
+133,592
New +$26.2M 1.1% 28

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Summit Partners Public Asset Management's UTHR Position: Q1 2023 in Review

Summit Partners Public Asset Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 36,878 shares — an estimated $10.3M sold.

Summit Partners Public Asset Management first reported a position in UTHR in Q4 2021 and held it in 2 quarters. The position peaked at $28.9M in Q4 2021. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Summit Partners Public Asset Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 36,878 United Therapeutics shares in Q1 2023, an estimated $10.3M.
  • Summit Partners Public Asset Management first reported a position in United Therapeutics in Q4 2021 and held it in 2 quarters.
  • Summit Partners Public Asset Management's United Therapeutics position peaked at $28.9M in Q4 2021.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2023, filed 15 May 2023.